Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Mesylates

Known as: Methanesulfonates, Mesylate, Mesilates 
Organic salts or esters of methanesulfonic acid.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
BACKGROUND Gastrointestinal stromal tumour is the most common sarcoma of the intestinal tract. Imatinib mesylate is a small… Expand
  • table 1
  • table 2
  • table 3
  • figure 3
  • figure 4
Highly Cited
2006
Highly Cited
2006
Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous… Expand
Highly Cited
2005
Highly Cited
2005
Recent breakthroughs regarding gastrointestinal stromal tumors (GIST) and their pathogenesis have redefined diagnostic criteria… Expand
Highly Cited
2004
Highly Cited
2004
Imatinib mesylate, an inhibitor of the Bcr-Abl tyrosine kinase, has modest activity in refractory/relapsed Philadelphia… Expand
  • table 1
  • table 2
  • table 2
  • table 2
  • figure 1
Highly Cited
2003
Highly Cited
2003
Inappropriate expression of the multidrug resistance (MDR1) gene encoding the P-glycoprotein (Pgp) has been frequently implicated… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2003
Highly Cited
2003
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) has shown remarkable… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 4
Highly Cited
2003
Highly Cited
2003
PURPOSE Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet… Expand
Highly Cited
2002
Highly Cited
2002
BACKGROUND Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal… Expand
  • table 2
  • figure 1
  • figure 2
  • table 3
  • figure 3
Highly Cited
2002
Highly Cited
2002
BACKGROUND Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia… Expand
Review
2002
Review
2002
This review discusses the development and uses of imatinib mesylate, a protein tyrosine kinase inhibitor useful in the treatment… Expand